Exchange: NASDAQ·Updated 07:41 PM EDT
AMGN logo

AMGNAMGEN Inc.

$363.39
$0.23
(0.06%)
Today
Closed $363.39
$0.27
(0.07%)
After Hours
EarningsAug 4
Mkt Cap$196.12B
Vol1.63M
News
all
press releases
How Safe Is Amgen's Dividend?
Key PointsAmgen is facing several legal and regulatory issues...
Nasdaq News: Markets
News Placeholder
More News
News Placeholder
If You Invested $100 In Amgen Stock 15 Years Ago, You Would Have This Much Today
Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 1.05% on an annualized basis producing an average annual return of 13.3%. Currently, Amgen has a market capitalization of $202.05 billion.read more...
Benzinga
News Placeholder
Amgen (AMGN) Stock Dips While Market Gains: Key Facts
Amgen (AMGN) closed the most recent trading day at $366.44, moving 2.06% from the previous trading session.
Zacks
News Placeholder
Amgen (AMGN) Upgraded to Buy: What Does It Mean for the Stock?
Amgen (AMGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
News Placeholder
Is Allarity Therapeutics, Inc. (ALLR) Stock Outpacing Its Medical Peers This Year?
Here is how Allarity Therapeutics, Inc. (ALLR) and Amgen (AMGN) have performed compared to their sector so far this year.
Zacks
News Placeholder
Roche Reports Positive Results From Head-to-Head Study on NSCLC Drug
RHHBY announces positive phase III Krascendo 1 results for divarasib in KRAS G12C NSCLC, showing PFS and OS gains versus approved inhibitors.
Zacks
News Placeholder
J&J's Innovative Medicine Business in Q2: Here's What to Watch
JNJ's Q2 Innovative Medicine results face scrutiny as Stelara biosimilar pressure offsets growth from key blockbusters and newer therapies ahead of earnings.
Zacks
News Placeholder
Amgen or Biogen: Which Biotech Stock Appears Better Poised?
AMGN stands out compared to Biogen given its broader product portfolio, pipeline depth and steadier growth outlook despite patent and competition risks.
Zacks
News Placeholder
Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage
Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified way to tap growth across the obesity treatment market.
Zacks
News Placeholder
Mizuho Highlights Amgen (AMGN) Pipeline Potential With MariTide and Olpasiran
Mizuho Highlights Amgen (AMGN) Pipeline Potential With MariTide and Olpasiran...
Yahoo! Finance: News
<
1
2
...
>

Advertisement|Remove ads.